Join us as our FDA experts provide an overview of Postmarketing Drug Safety Inspections for products regulated by the Center for Drug Evaluation and Research (CDER). These inspections include the Postmarketing Adverse Drug Experience (PADE) and Risk Evaluation and Mitigation Strategies (REMS) programs. During this extended webinar, we will provide an overview of the relevant laws and regulations, describe the PADE and REMS programs, and discuss points to consider for inspection.
Tuesday, June 19, 2018
10:00am - 2:00pm (Eastern)
This webinar has been pre-approved by RAPS as eligible for up to 4.0 credits towards a participant’s RAC recertification upon full completion. Only live attendance will qualify for the CE.
Attendance Certificates are only available for TWO WEEKS after the event
For questions concerning the webinar, please contact CDER SBIA at:
(866) 405-5367 | (301) 796-6707
No hay comentarios:
Publicar un comentario